Metabolic syndrome is not a single disease but a dangerous cluster: abdominal obesity, elevated triglycerides, low levels of protective HDL cholesterol, high fasting blood sugar and raised blood pressure. When at least three of these appear together, the risk of type 2 diabetes and cardiovascular disease climbs sharply. Globally, an estimated 12.5 to 31.4 percent of adults live with the condition, and its prevalence is rising, straining health systems and driving morbidity and mortality. What makes the syndrome so insidious is that its root cause, dysfunctional visceral fat wrapped around internal organs, is difficult to see and even harder to measure with a tape measure alone.

That is where VAI enters the picture. Introduced by Amato and colleagues in 2010, the index was originally modelled on 315 healthy nonobese subjects and validated in nearly 1,500 primary care patients. Unlike body mass index or waist circumference, which estimate fat quantity, VAI attempts to gauge fat function. Its formula combines waist circumference and BMI with triglycerides and HDL cholesterol, using different constants for men and women. In the original validation, VAI correlated inversely with insulin sensitivity measured by the gold-standard euglycemic-hyperinsulinemic clamp, while neither waist circumference nor BMI showed any correlation. It also independently predicted cardiovascular and cerebrovascular events, suggesting it was tapping into something the older measures missed.

The new study put the index through one of its most demanding real-world tests yet. Researchers analysed baseline data from 10,520 adults aged 35 to 70 enrolled in the PERSIAN Guilan Cohort in northern Iran. Participants underwent standardized physical examinations, structured interviews and fasting blood tests in a certified central laboratory. Metabolic syndrome was diagnosed using the ATP III criteria, requiring at least three of the five components. The results were striking: 40.7 percent of the cohort met the criteria, but the burden was heavily skewed by sex. Among men, prevalence was 24.5 percent; among women, it reached a remarkable 54.7 percent.

The numbers for VAI itself told a similar story. People with metabolic syndrome had a median VAI of 3.31, compared with 1.64 in those without the condition. In logistic regression models, each one-unit increase in VAI was associated with roughly 2.4-fold higher odds of metabolic syndrome, an association that barely budged after adjustment for age, sex, lipid-lowering medication, urban or rural residence, education, alcohol use and smoking. When participants were sorted into quartiles, the gradient was dramatic: odds ratios of 2.45, 9.42 and 41.35 for the second, third and fourth quartiles respectively, compared with the lowest.

Sex mattered. A formal interaction test confirmed that the association was significantly stronger in women than in men, with each unit of VAI carrying an odds ratio of 3.20 in women versus 1.92 in men. In the highest quartile, women faced 60.5-fold higher odds of metabolic syndrome compared with the lowest quartile, while men in the same position faced 55.2-fold higher odds. The researchers also examined each component of the syndrome separately. The strongest links were with elevated triglycerides and low HDL cholesterol, the two lipid parameters built into the VAI formula, but the index was also significantly associated with high fasting glucose, elevated blood pressure and increased waist circumference, components not directly embedded in the equation.

Diagnostic performance was assessed with receiver operating characteristic analysis. VAI alone achieved an area under the curve of 0.835 in the total population, with similar values in men and women, indicating good discrimination. Optimal cut-off points, derived using Youden’s Index, came out at 2.42 overall, 2.08 for men and 2.69 for women. Perhaps most tellingly, VAI outperformed every comparator tested: the triglyceride-to-HDL cholesterol ratio scored an AUC of 0.775, waist-to-height ratio 0.756, waist circumference 0.737 and body mass index just 0.715. The composite structure of the index, mixing anthropometric and biochemical signals, appears to capture cardiometabolic risk more effectively than any single measure.

The findings align with a widening international literature. A meta-analysis reported a pooled AUC of 0.847 for VAI in detecting metabolic syndrome, and studies in Spanish workers, Saudi cohorts, elderly Chinese adults and young adults have repeatedly shown the index matching or beating conventional measures. VAI has also proven relevant in high-risk groups, including women with polycystic ovary syndrome, patients with chronic kidney disease, people with suspected obstructive sleep apnea and children with obesity, where it often outperformed rivals such as the Lipid Accumulation Product and HOMA-IR. The consistency across ages, ethnicities and clinical settings hints that visceral fat dysfunction is a genuinely universal axis of metabolic disease.

The authors are careful about the caveats. Because the study is cross-sectional, it shows association with prevalent metabolic syndrome, not prospective prediction of future disease. More importantly, there is partial mathematical overlap: VAI incorporates waist circumference, triglycerides and HDL cholesterol, which are also components of the ATP III definition, so the enormous odds ratios in the top quartile should not be read as a purely independent biological effect. The skewed distribution of VAI, with a long upper tail, and the fact that the cut-off values were derived and tested in the same dataset add further caution. External validation in other populations and longitudinal follow-up will be essential before the thresholds can guide screening.

Even with those limitations, the practical appeal is obvious. VAI requires nothing more than a scale, a tape measure and two lipid values that are already ordered in routine check-ups, making it an attractive tool for early risk stratification, particularly in low- and middle-income countries where advanced imaging is scarce. The subgroup analyses showed the association held steady across age, marital status, education, occupation and BMI categories, suggesting robustness in diverse population segments. If future prospective studies confirm its predictive value, this unglamorous formula, multiplying a waist measurement by a ratio of blood fats, could become one of the cheapest and most effective gatekeepers against the coming wave of diabetes and heart disease.

Subject of Research: Association between the Visceral Adiposity Index and metabolic syndrome in the PERSIAN Guilan Cohort

Article Title: Association Between Visceral Adiposity Index and Metabolic Syndrome and Its Components: Evidence From the PERSIAN Guilan Cohort Study

Article References: Letafatkar, N., Amini‐Salehi, E., Hashemi, S. M., Hassanipour, S., Jafari, M., Ghaffari, S., Joukar, F., & Mansour‐Ghanaei, F. (2026). Association Between Visceral Adiposity Index and Metabolic Syndrome and Its Components: Evidence From the PERSIAN Guilan Cohort Study. Endocrinology, Diabetes & Metabolism, 9(5), Article e70341. https://doi.org/10.1002/edm2.70341

Image Credits: AI Generated

DOI: 10.1002/edm2.70341

Keywords: visceral adiposity index, metabolic syndrome, obesity, insulin resistance, triglycerides, HDL cholesterol, cardiometabolic risk, PERSIAN Guilan Cohort, Iran, epidemiology, BMI, screening

The follicular fluid that bathes a developing egg is far more than a passive medium. It is a carefully balanced soup of sugars, amino acids, lipids, and signaling molecules that the oocyte and its surrounding cumulus cells draw upon as they grow, acquire energy, and prepare for the extraordinary demands of fertilization and early embryonic development. Any chemical imbalance in this niche can ripple directly into the quality of the egg released or retrieved during in vitro fertilization. This is why the new study focused squarely on follicular fluid rather than blood: blood reflects whole-body metabolism, but follicular fluid captures the immediate microenvironment in which the oocyte actually lives. Sampling this fluid from patients undergoing IVF-ET procedures offers a rare window into the biology of the egg at the moment it matters most.

The technical approach was deliberately comprehensive. The researchers used ultra-high-performance liquid chromatography coupled with mass spectrometry to profile the metabolome without preconceptions about which molecules might be altered, then followed up with a targeted lipidomics platform designed to precisely quantify individual lipid species. Multivariate statistical tools, including principal component analysis and orthogonal partial least-squares discriminant analysis, separated the PCOS samples from controls, while univariate tests identified individual molecules that differed significantly between the groups. The team then layered on functional enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes, correlation analysis against clinical parameters such as body mass index, luteinizing hormone, anti-Müllerian hormone, and antral follicle count, and finally logistic regression and receiver operating characteristic modeling to test whether the altered molecules could serve as diagnostic biomarkers.

The headline finding is a striking pattern the authors describe as triglyceride accumulation alongside phospholipid depletion. In the follicular fluid of PCOS patients, lysophospholipids and glycerophospholipids—the workhorse fats of cellular membranes—were widely downregulated, while certain long-chain triglycerides selectively accumulated. Crucially, this redistribution was not random. The shifts showed structural selectivity based on carbon chain length and degree of unsaturation, meaning that specific lipid species with particular architectures were preferentially affected. Because phospholipids form the membranes of the oocyte and its supporting cells, and because membrane fluidity depends heavily on the fatty acid composition of those phospholipids, their depletion could compromise the structural and functional integrity of the egg itself. Meanwhile, the buildup of storage triglycerides suggests a shift in how follicular cells handle energy, hoarding fat in storage form rather than deploying it in membrane-building and signaling roles.

Beyond lipids, the metabolomic screen uncovered disturbances in several other biologically meaningful classes. Branched-chain amino acids, specifically D-leucine and L-valine, were elevated in PCOS follicular fluid. Elevated branched-chain amino acids are a well-recognized signature of insulin resistance, a condition that affects a large proportion of PCOS patients even when they are lean, and their accumulation in the follicular niche suggests that the metabolic derangements seen systemically in PCOS penetrate all the way to the egg’s doorstep. Excess branched-chain amino acids can also perturb the balance of other amino acid pools and generate metabolic byproducts that stress developing cells, adding another layer of potential harm to oocyte quality.

The study also documented a meaningful imbalance in steroid hormone metabolites within the follicular fluid. Progesterone, the hormone that normally rises to support ovulation and prepare the reproductive tract for a potential pregnancy, was reduced in PCOS samples, while 17α-estradiol, a less common estrogenic compound, was elevated. Steroid hormones are the master chemical communicators of the follicle, coordinating the final maturation of the egg, the timing of its release, and the receptivity of surrounding tissues. A shift in their relative proportions could therefore disrupt the finely choreographed sequence of events that culminates in a fertilizable oocyte, offering a chemical explanation for the ovulatory dysfunction that defines the syndrome.

Perhaps the most unexpected finding involved one-carbon metabolism and related pathways. The researchers observed significant depletion of tetrahydropteridine, cytosine, and uridine in PCOS follicular fluid. Tetrahydropteridine, in its biologically active form tetrahydrobiopterin, is an essential cofactor for enzymes that produce nitric oxide and neurotransmitters and is intimately linked to folate-dependent one-carbon metabolism, which supplies the methyl groups needed for DNA synthesis and epigenetic regulation. Cytosine and uridine are fundamental building blocks of RNA and DNA. Their depletion points to an impairment of the nucleotide supply and methylation machinery inside the follicular microenvironment, processes that are especially critical during the final stages of oocyte maturation, when the egg must stockpile the molecular machinery for the first rounds of embryonic cell division before its own genome is even activated.

When the metabolomic and lipidomic datasets were integrated, three core dysregulated networks emerged: glycerophospholipid metabolism, steroid hormone biosynthesis, and insulin resistance signaling. This convergence is significant because it ties together threads that are usually studied in isolation. The membrane lipid depletion connects to the steroid hormone imbalance, since steroidogenic enzymes operate within membranes whose lipid composition influences their function, and both connect to insulin resistance, which is known to drive excess ovarian androgen production and alter lipid handling throughout the body. The integrated analysis thus reframes PCOS as a polyendocrine metabolic disorder of the ovary, in which a single web of interconnected biochemical pathways links the metabolic syndrome-like features of the disease to its reproductive consequences at the level of the individual egg.

The diagnostic implications are equally compelling. Using logistic regression and ROC analysis, the team evaluated whether panels of the altered molecules could distinguish PCOS patients from controls, and the results point toward promising multi-marker panels for clinical auxiliary diagnosis. Current PCOS diagnosis relies on clinical criteria—irregular ovulation, biochemical or clinical signs of excess androgen, and the ultrasound appearance of polycystic ovaries—which can be ambiguous, particularly in adolescents or in patients whose presentations overlap with other conditions. A molecular signature drawn from follicular fluid, or potentially from more accessible compartments if the same disturbances are mirrored in blood, could one day provide an objective biochemical complement to these criteria, and might even help stratify patients by the specific metabolic mechanisms driving their disease.

The study’s limitations are those inherent to its design: the sample size of 30 patients per group is modest, the cross-sectional design captures a single moment in time, and follicular fluid can only be obtained from women already undergoing assisted reproduction, which may introduce selection effects. Validation in larger and more diverse cohorts, and longitudinal studies tracking whether these molecular signatures predict actual embryo implantation and live birth outcomes, will be essential next steps. Nevertheless, the comprehensive molecular map produced by this research offers a concrete mechanistic foundation for a question that has long frustrated reproductive medicine: why do eggs from women with PCOS so often develop poorly? The answer, it now appears, lies in a follicular microenvironment starved of membrane-building phospholipids, flooded with storage fat and branched-chain amino acids, shortchanged on nucleotide precursors and methylation cofactors, and awash in the wrong balance of steroid hormones—a chemical storm that the developing egg must weather before it ever has a chance to become an embryo.

Subject of Research: Metabolic and lipidomic dysregulation of the follicular fluid microenvironment in polycystic ovary syndrome

Article Title: Integrated metabolomic and targeted lipidomic profiling reveals systemic metabolic dysregulation in the follicular microenvironment of polycystic ovary syndrome

Article References: Yue, J., Tian, D., Yue, Y., Qi, X., Yan, L., Liu, Q., & Zhao, Y. (2026). Integrated metabolomic and targeted lipidomic profiling reveals systemic metabolic dysregulation in the follicular microenvironment of polycystic ovary syndrome. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02287-4

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02287-4

Keywords: PCOS, follicular fluid, metabolomics, lipidomics, oocyte quality, phospholipids, triglycerides, branched-chain amino acids, insulin resistance, steroid hormones, biomarkers, fertility

The study, led by Yan Yang and Danping Zhu of Chongqing Traditional Chinese Medicine Hospital together with Chunguang Xie of the Hospital of Chengdu University of Traditional Chinese Medicine, drew its participants from the China Health and Retirement Longitudinal Study, better known as CHARLS. This nationally representative survey follows community-dwelling Chinese adults over the age of 45 with detailed questionnaires, physical examinations, and blood biomarkers. From the CHARLS cohort, the researchers identified 2,980 individuals with impaired glucose metabolism, a category that encompasses prediabetes and diabetes, and tracked them for a median of three years. During that window, 440 participants experienced a first cardiovascular event, and 182 of those events were strokes, giving the team a meaningful number of outcomes with which to test their statistical models.

At the heart of the paper is a quantity called the cumulative C-reactive protein–triglyceride–glucose index, abbreviated cumCTI. To understand it, one must first unpack its parent measure, the triglyceride–glucose index, or TyG. The TyG index is calculated as the natural logarithm of fasting triglycerides multiplied by fasting glucose, divided by two. Because elevated triglycerides and elevated glucose are the biochemical hallmarks of insulin resistance, TyG has emerged over the past decade as a cheap, widely available proxy for how resistant a person’s tissues have become to insulin, without requiring the cumbersome insulin assays or glucose clamps that direct measurement demands. C-reactive protein, meanwhile, is a liver-produced protein that surges during systemic inflammation and has long been studied as a harbinger of cardiovascular disease.

The CTI fuses these concepts by multiplying TyG by the natural logarithm of C-reactive protein, on the theory that insulin resistance and inflammation act in concert to damage blood vessels. The cumulative version goes a step further: rather than taking a single snapshot, the researchers averaged CTI values measured at Wave 1 and Wave 3 of CHARLS, capturing repeated exposure over time. This cumulative approach matters biologically, because atherosclerosis is not driven by a single bad lab result but by years of sustained metabolic insult. A single measurement can be distorted by acute illness, recent meals, or laboratory variation, whereas a cumulative index smooths those fluctuations and better reflects a person’s long-running internal environment.

The results were consistent in direction but revealing in their details. In Cox proportional hazards models that sequentially adjusted for age, sex, and a battery of cardiovascular risk factors, each one-unit increase in cumCTI was associated with a 4.3 percent higher risk of overall cardiovascular disease and, more strikingly, a 9.0 percent higher risk of stroke. Both relationships followed a linear dose–response pattern, confirmed with restricted cubic splines, meaning risk rose steadily with the index rather than jumping only beyond some threshold. The association with stroke was stronger than the association with cardiovascular disease as a whole, a hint that the metabolic and inflammatory processes captured by the index may be particularly pertinent to cerebrovascular disease.

Yet the study’s most provocative findings came from its forensic dissection of what the index actually contains. Using weighted quantile sum regression, a technique designed to apportion the contribution of each component within a mixture, the researchers found that triglycerides carried 72.70 percent of the predictive weight for stroke and a full 80.78 percent for cardiovascular disease. C-reactive protein, the very ingredient added to create the fancier index, contributed a mere 0.20 percent to stroke prediction and only 7.81 percent to cardiovascular disease prediction. In other words, the incremental value of adding inflammation to the metabolic mix was nearly negligible, and the entire signal of the composite index was essentially riding on triglycerides.

The researchers also probed mechanism. Causal mediation analysis suggested that mean arterial pressure accounted for 15.6 percent of the effect of cumCTI on stroke and 12.5 percent of its effect on cardiovascular disease. This implies that part of the reason a high metabolic–inflammatory score precedes vascular events is that the same underlying dysfunction pushes blood pressure upward, which in turn damages arteries. For stroke specifically, blood pressure mediation was strongest, reinforcing the longstanding clinical axiom that hypertension is the dominant modifiable driver of cerebrovascular events and that glucose, lipids, and blood pressure should be managed as an integrated package rather than in isolation.

The statistical verdict on predictive performance, however, was the study’s most sobering conclusion. When the team compared models using Harrell’s C-index, a measure of how well a risk score discriminates between people who will and will not experience an event, the cumulative composite index scored 0.5639 while its simpler parent, the TyG index alone, scored 0.5744. A C-index of 0.5 represents chance-level discrimination, so both scores are modest predictors in absolute terms, but the crucial point is that the elaborate version did not beat the simple one. The extra blood draw, the added cost, and the added complexity of measuring C-reactive protein bought nothing. For population screening in resource-constrained settings, the authors conclude that TyG remains the more rational choice: cheaper, simpler, and no less informative.

Why does this matter beyond the statistics? Cardiovascular disease is the leading cause of death in China and much of the world, and people with impaired glucose metabolism face an elevated baseline risk that makes early identification especially valuable. If a two-component index computed from tests that cost pennies can flag higher-risk individuals, clinics can intervene earlier with lifestyle counseling, lipid-lowering therapy, and blood pressure control. Conversely, mandating inflammatory markers for everyone would inflate healthcare costs without improving triage. The study also delivers a broader methodological lesson for the biomarker literature: composite indices can sound impressive and publish well, but component-weighting analyses and head-to-head discrimination testing are essential to show whether a new score genuinely adds information or merely repackages the same signal under a longer name.

The findings come with caveats that the researchers themselves acknowledge implicitly. The follow-up period was short, with a median of three years, and both discrimination statistics were weak in absolute terms, so neither index is ready to serve as a standalone decision tool. The cohort comprised Chinese adults aged 45 and older with abnormal glucose metabolism, and whether the same component weights hold in younger populations, in other ethnic groups, or among people with normal glucose tolerance remains to be tested. Still, the paper’s central message is clear and clinically actionable. Among people with dysregulated blood sugar, sustained elevations in the triglyceride–glucose index track future cardiovascular and cerebrovascular events, partly through blood pressure, while C-reactive protein adds almost nothing to stroke prediction. Until more powerful risk models emerge, the humble TyG index, coupled with vigilant blood pressure management, appears to be the best low-cost screening strategy this line of research has produced.

Subject of Research: Prediction of cardiovascular disease and stroke risk using the cumulative C-reactive protein–triglyceride–glucose index in Chinese adults with impaired glucose metabolism

Article Title: The association between the cumulative C-reactive protein-triglyceride-glucose index and the incidence of cardiovascular disease in middle-aged and elderly Chinese individuals of abnormal glucose metabolism

Article References: Yang, Y., Xie, C., & Zhu, D. (2026). The association between the cumulative C-reactive protein-triglyceride-glucose index and the incidence of cardiovascular disease in middle-aged and elderly Chinese individuals of abnormal glucose metabolism. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02536-z

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02536-z

Keywords: cumCTI, TyG index, C-reactive protein, triglycerides, insulin resistance, cardiovascular disease, stroke, impaired glucose metabolism, CHARLS, cohort study, risk prediction, mean arterial pressure

The research, led by Yingchu Dai, Yufan Ling and Lu Hou with senior authorship from Leyuan Zhou, Hailong Pei and Wanshi Li, began with a retrospective analysis of 77 patients with non-small cell lung cancer, the most common form of lung malignancy worldwide. The team stratified the cohort according to serum triglyceride levels and followed outcomes over time. The differences were stark. Patients whose triglycerides exceeded 2.3 millimoles per litre showed significantly shorter overall survival than those in the normal range below 1.7 millimoles per litre, a difference that reached statistical significance with a log-rank p-value of 0.009. More striking still were the metastasis rates: 84.4 percent of hypertriglyceridemic patients displayed lymph node metastasis compared with just 37.9 percent of normotriglyceridemic patients, and distant metastasis was detected in 31.3 percent versus 3.4 percent respectively.

Those clinical associations set the stage for the mechanistic work. To test whether high triglycerides were merely a marker of poor health or an active participant in cancer progression, the researchers modelled hypertriglyceridemia in mice and examined how lung tumours behaved under those conditions. The animal data reinforced the human findings, showing reduced survival in tumour-bearing mice with elevated triglycerides. The team then turned to controlled laboratory systems, using extracellular matrix constrained invasion assays in non-small cell lung cancer cell lines. These assays recreate a critical physical barrier that metastasising cells must overcome in the body: the dense network of collagen and other proteins that forms the extracellular matrix, the biological scaffolding that anchors tissues together and that a migrating tumour cell must physically breach.

It is within this constrained microenvironment that the study’s central discovery emerges. The researchers found that triglycerides enhance lipid beta-oxidation, the cellular process by which fatty acids are broken down in mitochondria to generate energy. Rather than serving simply as inert fuel, this surge of lipid catabolism appeared to activate a signalling pathway centred on RhoA, a small GTP-binding protein well known to cell biologists as a master regulator of the actin cytoskeleton. When RhoA signalling intensified, tumour cells remodelled their internal scaffolding of actin filaments, gaining the mechanical force and structural plasticity needed to deform their bodies, push through narrow gaps in the matrix, and acquire what the authors describe as metastatic competence.

The technical logic of this axis deserves close attention. Triglycerides stored in lipid droplets must first be mobilised and transported into mitochondria, a step that depends on CPT1A, also known as CPT1A or carnitine palmitoyltransferase 1A, the rate-limiting enzyme of fatty acid import into mitochondria. The study’s figures trace this progression carefully: elevated neutral lipid levels enhanced tumour invasion potential in matrix-based assays, lipid depletion proved to be a prerequisite for tumour cell metastasis, and metastasising cells exhibited both enhanced lipid metabolism and pronounced actin cytoskeleton remodelling. Perhaps most intriguingly, the team found that RhoA promotes metastasis by enhancing the transcriptional activity of CPT1A, suggesting a feed-forward loop in which cytoskeletal signalling amplifies the very lipid-burning machinery that activates it.

To establish causality rather than mere correlation, the researchers deployed both pharmacological inhibition and genetic silencing. When they blocked CPT1A or RhoA, either with drugs or by knocking down the genes that encode them, the triglyceride-driven invasion and metastasis were significantly suppressed. This dual approach matters because it demonstrates that the lipid beta-oxidation and RhoA-driven cytoskeletal remodelling axis is not simply associated with metastatic behaviour but is functionally required for it. Interrupting the pathway at either node collapses the pro-metastatic effect of elevated triglycerides, which is precisely the kind of evidence needed to justify pursuing these molecules as therapeutic targets.

The findings sit within a rapidly expanding body of literature on cancer metabolism and metastasis. Previous work has shown that the fatty acid receptor CD36 marks metastasis-initiating cells in oral cancer, that the enzymes ACSL4 and polyunsaturated lipids support metastatic extravasation and colonisation, and that mechanical cues from the extracellular matrix can regulate lipid metabolism through the Lipin-1 and SREBP pathways. The new study adds an important directional insight: lipids are not only passive building blocks or energy reserves for migrating cells but can actively trigger the mechanical programming that makes migration possible. The link between membrane lipid milieu and Rho-family signalling had been hinted at in earlier work on peroxisomal beta-oxidation, and the cytoskeleton’s role in controlling lipid droplet movement and storage has been documented, but the demonstration that this circuitry operates in the context of systemic hypertriglyceridemia and lung cancer metastasis is novel.

The clinical implications are potentially significant. Elevated serum triglycerides are extraordinarily common, driven by diet, obesity, diabetes and genetic factors, and they are already a recognised risk factor for cardiovascular disease. If the mechanism described here holds in broader patient populations, then triglyceride management could become a meaningful component of supportive care in non-small cell lung cancer, and lipid-lowering interventions might be evaluated not only for heart health but for their potential to reduce metastatic risk. More immediately, the identification of CPT1A and RhoA as druggable nodes in the pathway suggests that inhibitors of fatty acid oxidation, some of which are already in clinical development for other cancers, could be repurposed or combined with existing treatments for patients with hypertriglyceridemia-associated lung tumours.

Important caveats remain. The human component of the study was retrospective and involved a relatively modest cohort of 77 patients, so prospective validation in larger and more diverse populations will be essential before triglyceride levels can be incorporated into prognostic models or treatment decisions. The mouse and cell-line experiments, while mechanistically rigorous, capture only parts of the complexity of human tumour biology, and the interplay between triglycerides, immune cells, the lymphatic vasculature and other microenvironmental factors remains to be fully explored. The authors also note that their data were generated with appropriate ethical oversight, with approval from the Ethics Committee of Soochow University and informed consent from all patients, and that datasets are available from the corresponding author upon reasonable request.

Nevertheless, the study represents a compelling example of how a systemic metabolic condition can be connected, step by step, to the cellular physics of cancer spread. By showing that triglycerides fuel beta-oxidation, that beta-oxidation activates RhoA, and that RhoA-driven cytoskeletal remodelling enables tumour cells to overcome the mechanical constraints of the extracellular matrix, the researchers have transformed a statistical association into a testable, targetable pathway. As metastasis remains the leading cause of death in lung cancer, strategies that target lipid catabolism and cytoskeletal dynamics may open a new front in the effort to keep the disease localised, offering hope that something as routine as a blood lipid panel could one day help identify which patients need the most aggressive intervention.

Subject of Research: The role of triglyceride-driven lipid beta-oxidation and RhoA cytoskeletal signalling in non-small cell lung cancer metastasis

Article Title: Triglyceride enhancs NSCLC metastasis via lipid β-oxidation by RhoA-driven cytoskeletal remodeling in ECM-constrained microenvironments

Article References: Dai, Y., Ling, Y., Hou, L., Yang, T., Gu, Q., Fang, Y., Li, W., Pei, H., & Zhou, L. (2026). Triglyceride enhancs NSCLC metastasis via lipid β-oxidation by RhoA-driven cytoskeletal remodeling in ECM-constrained microenvironments. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03586-9

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03586-9

Keywords: non-small cell lung cancer, triglycerides, metastasis, lipid beta-oxidation, RhoA, CPT1A, cytoskeleton, extracellular matrix, cancer metabolism, hypertriglyceridemia, British Journal of Cancer, Triglyceride

Evinacumab’s story begins not in a pharmaceutical laboratory but in human DNA. Angiopoietin-like protein 3, or ANGPTL3, is a protein secreted by the liver that acts as a molecular brake on two key fat-processing enzymes: lipoprotein lipase and endothelial lipase. People born with rare loss-of-function mutations in the ANGPTL3 gene enjoy lifelong low levels of triglycerides and LDL cholesterol and, crucially, a substantially reduced risk of atherosclerotic cardiovascular disease. Large population studies and Mendelian randomization analyses confirmed that these genetic effects are causal, transforming ANGPTL3 from a curious biological observation into one of the most validated drug targets in modern cardiovascular medicine.

Evinacumab is a fully human IgG4 monoclonal antibody that binds and neutralizes ANGPTL3. By lifting the inhibitory brake that ANGPTL3 places on lipoprotein lipase, the drug accelerates the hydrolysis and clearance of triglyceride-rich lipoproteins and their remnants. Enhanced endothelial lipase activity, meanwhile, promotes lipoprotein remodeling and modulates HDL metabolism. What makes the drug especially valuable, however, is a second, independent mechanism: ANGPTL3 inhibition lowers LDL cholesterol through pathways that do not require functional LDL receptors. It speeds the processing of very-low-density and intermediate-density lipoproteins and clears their remnants before they can mature into LDL particles, an endothelial lipase-dependent route that bypasses the receptor defect at the heart of familial hypercholesterolemia.

That receptor independence is precisely why the drug matters for homozygous familial hypercholesterolemia, or HoFH, the most severe inherited form of high cholesterol. Patients with HoFH carry mutations in both copies of genes governing the LDL receptor pathway, leaving them with sky-high cholesterol from birth, accelerated atherosclerosis, and little response to statins, ezetimibe, or even PCSK9 inhibitors. The new review, conducted under PRISMA guidelines and registered in PROSPERO, gathered evidence from randomized controlled trials, open-label extensions, pediatric studies, and real-world cohorts to quantify just how much evinacumab helps this population.

The quantitative core of the analysis focused on 357 patients with hypercholesterolemia receiving the approved regimen of 15 milligrams per kilogram intravenously every four weeks. Across seven pooled studies, evinacumab reduced LDL cholesterol by an average of 48.56 percent, non-HDL cholesterol by 50.19 percent, apolipoprotein B by 40.51 percent, and triglycerides by 53.13 percent. Study-level LDL reductions ranged from 42 to 82 percent, but most cohorts clustered near the 50 percent mark despite patients already being on maximally tolerated lipid-lowering therapy. Sensitivity analyses that dropped one study at a time confirmed the robustness of the results, and long-term extension data together with real-world experience showed the effects are sustained over time.

The real-world evidence carries particular weight for clinicians. In observational cohorts, evinacumab enabled some patients to reduce or even discontinue lipoprotein apheresis, the grueling blood-filtering procedure that has long been the last resort for HoFH. Similar efficacy was observed in pediatric populations, and isolated reports describe regression of atherosclerotic plaque in severely affected young patients treated with intensive regimens that included the antibody. Regulators have taken note: the United States Food and Drug Administration has approved evinacumab for HoFH patients aged one year and older, the European Medicines Agency for patients from six months of age, and the latest European and American cholesterol guidelines have woven the drug into their treatment algorithms for patients who fail LDL targets on receptor-dependent therapies.

The picture in hypertriglyceridemia is more complicated, and more nuanced. Because the underlying trials did not report variability measures, the authors could only assess this field qualitatively. Early phase 1 work showed dose-dependent triglyceride reductions reaching 70 to 80 percent at the highest doses, and in patients with moderate hypertriglyceridemia triglycerides fell 81.8 percent versus 20.6 percent on placebo. But the story diverged by syndrome. In multifactorial chylomicronemia syndrome, where patients retain some residual lipoprotein lipase function, triglyceride reductions frequently exceeded 60 to 80 percent, and a phase 2b trial in pancreatitis-prone patients showed median triglyceride drops of 55.3 percent at four weeks and up to 95.7 percent by week 16. In familial chylomicronemia syndrome, where lipoprotein lipase is essentially absent, responses were far more limited and largely indistinguishable from placebo, suggesting that residual enzyme activity is a biological prerequisite for the drug’s triglyceride-lowering power.

Another clinically important wrinkle emerged: in some hypertriglyceridemic cohorts, LDL cholesterol transiently rose, in certain cases by more than 50 percent. The authors explain this counterintuitive effect through lipoprotein kinetics. Profoundly accelerated lipolysis of triglyceride-rich particles can transiently generate more remnant particles and LDL precursors, occasionally nudging measured LDL upward even as triglycerides plummet. In this setting, the authors argue, such shifts may be of secondary importance, because the primary therapeutic objective is preventing acute pancreatitis, a life-threatening complication of extreme triglyceride elevations. Still, the observation underscores that evinacumab’s effects are phenotype-dependent, and that monitoring strategies must adapt to the patient in front of the clinician.

The review is candid about its limitations. Clinical and methodological heterogeneity across the 17 studies precluded a global comparative meta-analysis, forcing the authors to restrict quantitative pooling to hypercholesterolemic patients on the approved dose. Potential overlap of participants across trials, extension studies, and real-world reports from the same development programs cannot be fully excluded, which may have artificially sharpened some pooled estimates, and the small number of studies made formal publication bias testing unreliable. Risk-of-bias assessment rated most randomized trials at low risk or with some concerns, while several non-randomized studies carried moderate to serious risk. Even so, the overall verdict is strikingly consistent: evinacumab delivers substantial, sustained lipid lowering, most convincingly in HoFH, where it achieves the near-impossible, roughly halving LDL cholesterol in patients whose receptors cannot do the job. Emerging evidence also supports a role in severe hypertriglyceridemia, especially multifactorial chylomicronemia, though the authors caution that further studies are needed to translate triglyceride reductions into proven reductions in pancreatitis and cardiovascular events. For a drug built on the biology of lucky mutants, evinacumab is rapidly becoming anything but a niche option.

Subject of Research: Efficacy of the ANGPTL3 inhibitor evinacumab across different lipid phenotypes

Article Title: Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis

Article References: Masson, W., Lobo, M., Mansur, M., Solis, C., & Nogueira, J. P. (2026). Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis. Advances in Therapy. https://doi.org/10.1007/s12325-026-03783-1

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03783-1

Keywords: evinacumab, ANGPTL3, LDL cholesterol, homozygous familial hypercholesterolemia, hypertriglyceridemia, chylomicronemia syndrome, monoclonal antibody, systematic review, meta-analysis, triglycerides, cardiovascular disease, lipid metabolism

Chronic kidney disease is a slow, often silent condition in which the kidneys progressively lose their ability to filter waste from the blood. Because symptoms frequently do not appear until substantial function has been lost, researchers have long searched for early, readily measurable signals that identify people at risk before the damage becomes irreversible. Dyslipidemia—an abnormal level of lipids in the blood—is extremely common in patients who already have CKD, typically manifesting as elevated triglycerides, reduced high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels that are normal or only slightly raised. What has remained less clear is whether this distinctive dyslipidemic pattern precedes the onset of kidney disease and can therefore serve as a warning sign rather than simply a consequence.

To address that question, the research team, led by Dandan Li of the First Affiliated Hospital of Henan University of Science and Technology and colleagues at Huaihe Hospital of Henan University and collaborating institutions in China, analyzed data from adults aged 40 years and older whose baseline estimated glomerular filtration rate (eGFR)—the standard measure of kidney filtering capacity—exceeded 60 mL/min/1.73 m². The participants were followed for six years. The team examined eight lipid parameters: triglycerides (TG), total cholesterol (TC), HDL-C, LDL-C, the triglyceride-to-HDL-C ratio (TG/HDL-C), the total-cholesterol-to-HDL-C ratio (TC/HDL-C), the non-HDL-cholesterol-to-HDL-C ratio (NHHR), and residual cholesterol (RC), a measure of cholesterol carried in triglyceride-rich lipoprotein remnants that is increasingly studied for its role in cardiovascular disease.

The main outcome was carefully defined: incident CKD was recorded when a participant’s eGFR fell by at least 30 percent from its baseline value and finished the follow-up period below 60 mL/min/1.73 m². This dual criterion helps ensure that the classification captures a genuine, clinically meaningful decline in kidney function rather than ordinary measurement variability. Using multivariate logistic regression, the researchers adjusted for a range of potential confounders, including demographic factors and clinical covariates, and employed restricted cubic spline analyses to explore the shape of the relationships and subgroup analyses to test whether the associations differed across patient characteristics.

The results were striking in their consistency. Over the six years of follow-up, 453 of the 3,856 participants—11.7 percent of the cohort—developed incident CKD. After full statistical adjustment, participants in the highest tertile of log-transformed triglycerides had 59 percent higher odds of developing CKD compared with those in the lowest tertile, with an odds ratio of 1.59 and a 95 percent confidence interval of 1.24 to 2.05. Total cholesterol told a similar story, with an odds ratio of 1.49 (95 percent CI: 1.15 to 1.92) for the highest versus lowest tertile.

The composite indices performed at least as well as the conventional parameters. The TC/HDL-C ratio was associated with an odds ratio of 1.51 (95 percent CI: 1.17 to 1.95), while the TG/HDL-C ratio produced the largest effect estimate in the analysis, at 1.63 (95 percent CI: 1.26 to 2.10). The non-HDL-cholesterol-to-HDL-C ratio, a composite measure that captures the balance between atherogenic and protective cholesterol fractions, yielded an odds ratio of 1.51 (95 percent CI: 1.17 to 1.95), and residual cholesterol was associated with an odds ratio of 1.50 (95 percent CI: 1.18 to 1.92). In other words, every one of the pro-atherogenic lipid measures examined—whether conventional or composite—pointed in the same direction: higher levels corresponded to higher odds of future kidney disease.

There was one notable exception, and it was protective. Higher levels of HDL-C, often described as the “good” cholesterol because of its role in reverse cholesterol transport, were associated with lower odds of incident CKD, with an odds ratio of 0.75 (95 percent CI: 0.58 to 0.96). This inverse relationship fits mechanistically with HDL’s established anti-inflammatory and antioxidant functions, which some researchers believe may extend to protecting the delicate filtration structures of the kidney from lipid-mediated injury.

The subgroup analyses added an intriguing nuance. Most of the associations held steady across prespecified subgroups of participants, but the TG/HDL-C ratio showed a higher effect estimate in people without diabetes. This observation is scientifically interesting because diabetic kidney disease has its own well-characterized risk architecture; the suggestion that the triglyceride-HDL balance may be an especially informative predictor among non-diabetic adults raises the possibility that composite lipid indices could help identify kidney risk in a population where clinical vigilance is often lower. The authors also employed restricted cubic spline analysis, a flexible statistical technique that models non-linear dose-response relationships, to characterize how risk varied across the full range of lipid values rather than only at arbitrary cutoffs.

From a mechanistic standpoint, several pathways could link lipid disturbances to kidney damage. Elevated triglycerides and residual cholesterol reflect an abundance of triglyceride-rich lipoproteins and their remnants, particles that can deposit in tissues, provoke inflammation, and injure the glomeruli—the microscopic filtration units of the kidney. Lipid accumulation within kidney cells can trigger oxidative stress and fibrosis, processes that progressively scar renal tissue and erode filtering capacity. At the same time, the possibility of reverse causation cannot be fully dismissed in an observational, retrospective design: subtle early kidney dysfunction may itself alter lipid metabolism, and the study’s reliance on routinely collected clinical data means that unmeasured confounding remains a possibility. The authors note that the study received no external funding and was approved by the Clinical Research Ethics Committee of Huaihe Hospital, Henan University, which waived individual informed consent owing to the retrospective nature of the analysis.

The practical implications, however, are immediately relevant to everyday medicine. Lipid panels are among the most commonly ordered laboratory tests in the world, and the parameters highlighted in this study—triglycerides, HDL-C, and simple ratios derived from them—require no additional blood draws, no specialized equipment, and no added cost. If the findings are confirmed in prospective and ethnically diverse cohorts, clinicians could conceivably incorporate composite lipid indices into routine kidney risk stratification, flagging patients whose blood fat profiles warrant closer monitoring of eGFR and earlier intervention with lifestyle modification or lipid-lowering therapy. With chronic kidney disease affecting hundreds of millions of people globally and often progressing unnoticed until dialysis or transplantation becomes necessary, the idea that a number already printed on nearly every routine lab report might help predict who will lose kidney function is a compelling—and potentially consequential—step forward for preventive nephrology.

Subject of Research: The association between conventional and composite blood lipid parameters and the risk of developing incident chronic kidney disease in adults

Article Title: Lipid parameters and the risk of incident CKD: an analysis of conventional and composite lipid indices

Article References: Li, D., Song, Z., Wang, X., Xu, H., Li, X., Yan, S., Yu, T., Liu, Y., Liu, Z., & Jiang, H. (2026). Lipid parameters and the risk of incident CKD: an analysis of conventional and composite lipid indices. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02529-y

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02529-y

Keywords: chronic kidney disease, triglycerides, HDL cholesterol, LDL cholesterol, lipid ratios, residual cholesterol, dyslipidemia, eGFR, cohort study, nephrology, cardiovascular risk, kidney disease prevention